Unknown

Dataset Information

Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes.


ABSTRACT:

Background

Olaparib (Lynparza™) is a PARP inhibitor approved for advanced BRCA-mutated (BRCAm) ovarian cancer. PARP inhibitors may benefit patients whose tumours are dysfunctional in DNA repair mechanisms unrelated to BRCA1/2. We report exploratory analyses, including the long-term outcome of candidate biomarkers of sensitivity to olaparib in BRCA wild-type (BRCAwt) tumours.

Methods

Tumour samples from an olaparib maintenance monotherapy trial (Study 19, D0810C00019; NCT00753545) were analysed. Analyses included classification of mutations in genes involved in homologous recombination repair (HRR), BRCA1 promoter methylation status, measurement of BRCA1 protein and Myriad HRD score.

Results

Patients with BRCAm tumours gained most benefit from olaparib; a similar treat

SUBMITTER: Hodgson DR 

PROVIDER: S-EPMC6265286 | biostudies-literature | 2018 Nov

REPOSITORIES: biostudies-literature